Sarepta Therapeutics annual revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Revenue Growth & History (SRPT)
Sarepta Therapeutics reported $1.86B in revenue for fiscal 2025, an increase of 4.27% from the previous fiscal year.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.86B | $76.3M | +4.27% |
| 2024 | 2024-12-31 | $1.79B | $643.1M | +56.17% |
| 2023 | 2023-12-31 | $1.14B | $301.1M | +35.69% |
| 2022 | 2022-12-31 | $843.8M | $231.4M | +37.78% |
| 2021 | 2021-12-31 | $612.4M | $156.5M | +34.34% |
| 2020 | 2020-12-31 | $455.9M | $75.0M | +19.70% |
| 2019 | 2019-12-31 | $380.8M | $79.8M | +26.51% |
| 2018 | 2018-12-31 | $301.0M | $146.4M | +94.74% |
| 2017 | 2017-12-31 | $154.6M | $149.2M | +2751.58% |
| 2016 | 2016-12-31 | $5.4M | $4.2M | +332.64% |
| 2015 | 2015-12-31 | $1.3M | −$8.5M | −87.16% |
| 2014 | 2014-12-31 | $9.8M | −$4.5M | −31.38% |
| 2013 | 2013-12-31 | $14.2M | −$23.1M | −61.91% |
| 2012 | 2012-12-31 | $37.3M | −$9.7M | −20.56% |
| 2011 | 2011-12-31 | $47.0M | $17.6M | +59.72% |
| 2010 | 2010-12-31 | $29.4M | — | — |
Sarepta Therapeutics quarterly revenue
Q2.11
Q3.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q4.15
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $328.7M | −$184.4M | −35.94% |
| Q1 2026 | 2026-03-31 | $330.5M | −$281.0M | −45.95% |
| Q4 2025 | 2025-12-31 | $442.9M | −$215.5M | −32.73% |
| Q3 2025 | 2025-09-30 | $370.0M | −$59.7M | −13.90% |
| Q2 2025 | 2025-06-30 | $513.1M | $152.6M | +42.32% |
| Q1 2025 | 2025-03-31 | $611.5M | $252.0M | +70.11% |
| Q4 2024 | 2024-12-31 | $658.4M | $293.3M | +80.35% |
| Q3 2024 | 2024-09-30 | $429.8M | $120.4M | +38.94% |
| Q2 2024 | 2024-06-30 | $360.5M | $121.6M | +50.86% |
| Q1 2024 | 2024-03-31 | $359.5M | $128.0M | +55.29% |
| Q4 2023 | 2023-12-31 | $365.1M | $129.1M | +54.74% |
| Q3 2023 | 2023-09-30 | $309.3M | $101.5M | +48.87% |
| Q2 2023 | 2023-06-30 | $239.0M | $27.8M | +13.14% |
| Q1 2023 | 2023-03-31 | $231.5M | $42.7M | +22.60% |
| Q4 2022 | 2022-12-31 | $235.9M | $57.2M | +32.01% |
| Q3 2022 | 2022-09-30 | $207.8M | $40.9M | +24.48% |
| Q2 2022 | 2022-06-30 | $211.2M | $69.4M | +48.93% |
| Q1 2022 | 2022-03-31 | $188.8M | $63.9M | +51.15% |
| Q4 2021 | 2021-12-31 | $178.7M | $56.1M | +45.73% |
| Q3 2021 | 2021-09-30 | $166.9M | $45.5M | +37.46% |
| Q2 2021 | 2021-06-30 | $141.8M | $30.5M | +27.39% |
| Q1 2021 | 2021-03-31 | $124.9M | $24.5M | +24.37% |
| Q4 2020 | 2020-12-31 | $122.6M | $22.5M | +22.51% |
| Q3 2020 | 2020-09-30 | $121.4M | $22.4M | +22.60% |
| Q2 2020 | 2020-06-30 | $111.3M | $16.7M | +17.62% |
| Q1 2020 | 2020-03-31 | $100.4M | $13.4M | +15.44% |
| Q4 2019 | 2019-12-31 | $100.1M | $15.7M | +18.60% |
| Q3 2019 | 2019-09-30 | $99.0M | $20.6M | +26.19% |
| Q2 2019 | 2019-06-30 | $94.7M | $21.1M | +28.75% |
| Q1 2019 | 2019-03-31 | $87.0M | $22.4M | +34.68% |
| Q4 2018 | 2018-12-31 | $84.4M | $27.1M | +47.38% |
| Q3 2018 | 2018-09-30 | $78.5M | $32.5M | +70.79% |
| Q2 2018 | 2018-06-30 | $73.5M | $38.5M | +110.02% |
| Q1 2018 | 2018-03-31 | $64.6M | $48.3M | +295.32% |
| Q4 2017 | 2017-12-31 | $57.3M | $51.9M | +956.58% |
| Q3 2017 | 2017-09-30 | $46.0M | — | — |
| Q2 2017 | 2017-06-30 | $35.0M | — | — |
| Q1 2017 | 2017-03-31 | $16.3M | — | — |
| Q4 2016 | 2016-12-31 | $5.4M | $4.2M | +332.64% |
| Q4 2015 | 2015-12-31 | $1.3M | $1.2M | +4540.74% |
| Q4 2014 | 2014-12-31 | $27,000 | −$2.6M | −98.97% |
| Q3 2014 | 2014-09-30 | $1.1M | −$3.1M | −74.59% |
| Q2 2014 | 2014-06-30 | $2.6M | −$368,000 | −12.47% |
| Q1 2014 | 2014-03-31 | $6.1M | $1.6M | +36.08% |
| Q4 2013 | 2013-12-31 | $2.6M | −$4.7M | −64.20% |
| Q3 2013 | 2013-09-30 | $4.2M | −$3.4M | −44.97% |
| Q2 2013 | 2013-06-30 | $3.0M | −$8.3M | −73.67% |
| Q1 2013 | 2013-03-31 | $4.5M | −$6.7M | −60.10% |
| Q4 2012 | 2012-12-31 | $7.3M | — | — |
| Q3 2012 | 2012-09-30 | $7.6M | $50,000 | +0.66% |
| Q2 2012 | 2012-06-30 | $11.2M | −$378,000 | −3.26% |
| Q1 2012 | 2012-03-31 | $11.2M | — | — |
| Q3 2011 | 2011-09-30 | $7.5M | — | — |
| Q2 2011 | 2011-06-30 | $11.6M | — | — |
Sarepta Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue grew from $455.9M to $1.86B, a compound annual growth rate of 32.54%. Sarepta Therapeutics's latest reported quarter, Q2 2026, generated $328.7M in revenue, a decrease of 35.94% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...
